Dermata Therapeutics, Inc. – NASDAQ:DRMAW
Dermata Therapeutics stock price today
Dermata Therapeutics stock price monthly change
Dermata Therapeutics stock price quarterly change
Dermata Therapeutics stock price yearly change
Dermata Therapeutics key metrics
Market Cap | 2.15M |
Enterprise value | N/A |
P/E | -0.01 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.04 |
PEG ratio | 0.13 |
EPS | -8.77 |
Revenue | N/A |
EBITDA | -8.96M |
Income | -8.68M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDermata Therapeutics stock price history
Dermata Therapeutics stock forecast
Dermata Therapeutics financial statements
| Jun 2023 | 0 | -1.70M | |
|---|---|---|---|
| Sep 2023 | 0 | -1.71M | |
| Dec 2023 | 0 | -2.13M | |
| Mar 2024 | 0 | -3.13M |
| Jun 2023 | 8712881 | 682.86K | 7.84% |
|---|---|---|---|
| Sep 2023 | 7323383 | 916.81K | 12.52% |
| Dec 2023 | 7978634 | 1.62M | 20.35% |
| Mar 2024 | 5179756 | 1.37M | 26.48% |
| Jun 2023 | -1.84M | 0 | 1.51M |
|---|---|---|---|
| Sep 2023 | -1.77M | 0 | -35.41K |
| Dec 2023 | -1.14M | 0 | 1.95M |
| Mar 2024 | -2.70M | 0 | 0 |
Dermata Therapeutics alternative data
| Aug 2023 | 7 |
|---|---|
| Sep 2023 | 7 |
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 8 |
| Feb 2024 | 8 |
| Mar 2024 | 8 |
| Apr 2024 | 8 |
| May 2024 | 8 |
| Jun 2024 | 8 |
| Jul 2024 | 8 |
Dermata Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Aug 2021 | 71428 | 0 |
| Nov 2021 | 20000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | PROEHL GERALD T director, 10 perc.. | Common Stock | 20,000 | $2.4 | $48,000 | ||
Purchase | HALE DAVID F director, 10 percent owner | Warrant to Purchase Common Stock | 71,428 | $7 | $499,996 |
-
What's the price of Dermata Therapeutics stock today?
One share of Dermata Therapeutics stock can currently be purchased for approximately $0.02.
-
When is Dermata Therapeutics's next earnings date?
Unfortunately, Dermata Therapeutics's (DRMAW) next earnings date is currently unknown.
-
Does Dermata Therapeutics pay dividends?
No, Dermata Therapeutics does not pay dividends.
-
How much money does Dermata Therapeutics make?
Dermata Therapeutics has a market capitalization of 2.15M.
-
What is Dermata Therapeutics's stock symbol?
Dermata Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "DRMAW".
-
What is Dermata Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Dermata Therapeutics?
Shares of Dermata Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Dermata Therapeutics have?
As Jul 2024, Dermata Therapeutics employs 8 workers.
-
When Dermata Therapeutics went public?
Dermata Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 13 Aug 2021.
-
What is Dermata Therapeutics's official website?
The official website for Dermata Therapeutics is dermatarx.com.
-
Where are Dermata Therapeutics's headquarters?
Dermata Therapeutics is headquartered at 3525 Del Mar Heights Road, San Diego, CA.
-
How can i contact Dermata Therapeutics?
Dermata Therapeutics's mailing address is 3525 Del Mar Heights Road, San Diego, CA and company can be reached via phone at 858 800 2543.
Dermata Therapeutics company profile:
Dermata Therapeutics, Inc.
dermatarx.comNASDAQ
8
Biotechnology
Healthcare
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
San Diego, CA 92130
CIK: 0001853816
ISIN: US2498451168
CUSIP: 249845116
